Potentiating the Cross-Reactive IFN-γ T Cell and Polyfunctional T Cell Responses by Heterologous GX-19N DNA Booster in Mice Primed with Either a COVID-19 mRNA Vaccine or Inactivated Vaccine

被引:1
|
作者
Seo, Yong Bok [1 ]
Ko, Ara [1 ]
Shin, Duckhyang [2 ]
Kim, Junyoung [1 ]
Suh, You Suk [2 ]
Na, Juyoung [2 ]
Ryu, Ji In [1 ]
Lee, Suyeon [1 ]
Oh, Min Ji [1 ]
Sung, Young Chul [2 ,3 ]
机构
[1] SL VaxiGen Inc, Res Inst, Korea Bio Pk, Seongnam 13488, South Korea
[2] Genexine Inc, Res Inst, Korea Bio Pk, Seongnam 13488, South Korea
[3] Pohang Univ Sci & Technol POSTECH, Dept Life Sci, Pohang 37673, South Korea
关键词
SARS-CoV-2; COVID-19; DNA vaccine; mRNA vaccine; TH1;
D O I
10.3390/ijms24119753
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Waning vaccine-induced immunity, coupled with the emergence of SARS-CoV-2 variants, has inspired the widespread implementation of COVID-19 booster vaccinations. Here, we evaluated the potential of the GX-19N DNA vaccine as a heterologous booster to enhance the protective immune response to SARS-CoV-2 in mice primed with either an inactivated virus particle (VP) or an mRNA vaccine. We found that in the VP-primed condition, GX-19N enhanced the response of both vaccine-specific antibodies and cross-reactive T Cells to the SARS-CoV-2 variant of concern (VOC), compared to the homologous VP vaccine prime-boost. Under the mRNA-primed condition, GX-19N induced higher vaccine-induced T Cell responses but lower antibody responses than the homologous mRNA vaccine prime-boost. Furthermore, the heterologous GX-19N boost induced higher S-specific polyfunctional CD4(+) and CD8(+) T cell responses than the homologous VP or mRNA prime-boost vaccinations. Our results provide new insights into booster vaccination strategies for the management of novel COVID-19 variants.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses
    Philippe Moris
    Robbert van der Most
    Isabel Leroux-Roels
    Frédéric Clement
    Mamadou Dramé
    Emmanuel Hanon
    Geert G. Leroux-Roels
    Marcelle Van Mechelen
    Journal of Clinical Immunology, 2011, 31 : 443 - 454
  • [32] Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice
    Adrian Rice
    Mohit Verma
    Annie Shin
    Lise Zakin
    Peter Sieling
    Shiho Tanaka
    Joseph Balint
    Kyle Dinkins
    Helty Adisetiyo
    Brett Morimoto
    Wendy Higashide
    C. Anders Olson
    Shivani Mody
    Patricia Spilman
    Elizabeth Gabitzsch
    Jeffrey T. Safrit
    Shahrooz Rabizadeh
    Kayvan Niazi
    Patrick Soon-Shiong
    Scientific Reports, 11
  • [33] Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice
    Rice, Adrian
    Verma, Mohit
    Shin, Annie
    Zakin, Lise
    Sieling, Peter
    Tanaka, Shiho
    Balint, Joseph
    Dinkins, Kyle
    Adisetiyo, Helty
    Morimoto, Brett
    Higashide, Wendy
    Olson, C. Anders
    Mody, Shivani
    Spilman, Patricia
    Gabitzsch, Elizabeth
    Safrit, Jeffrey T.
    Rabizadeh, Shahrooz
    Niazi, Kayvan
    Soon-Shiong, Patrick
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [34] Temporal evolution of humoral and T-cell specific immune response to COVID-19 mRNA vaccine in multiple sclerosis
    Ruggieri, S.
    Tortorella, C.
    Aiello, A.
    Farroni, C.
    Haggiag, S.
    Prosperini, L.
    Cuzzi, G.
    Salmi, A.
    Quartuccio, M. E.
    Vanin, V.
    Altera, A. M. G.
    Garbuglia, A. R.
    Lapa, D.
    Meschi, S.
    Maffongelli, G.
    Bartoli, T. Ascoli
    Galgani, S.
    Nicastri, E.
    Gasperini, C.
    Goletti, D.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 606 - 607
  • [35] Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose
    Ruggieri, Serena
    Aiello, Alessandra
    Tortorella, Carla
    Navarra, Assunta
    Vanini, Valentina
    Meschi, Silvia
    Lapa, Daniele
    Haggiag, Shalom
    Prosperini, Luca
    Cuzzi, Gilda
    Salmi, Andrea
    Quartuccio, Maria Esmeralda
    Altera, Anna Maria Gerarda
    Garbuglia, Anna Rosa
    Ascoli Bartoli, Tommaso
    Galgani, Simonetta
    Notari, Stefania
    Agrati, Chiara
    Puro, Vincenzo
    Nicastri, Emanuele
    Gasperini, Claudio
    Goletti, Delia
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (10)
  • [36] B and T cell responses to the BNT162b2 COVID-19 mRNA vaccine are not impaired in germ-free or antibiotic-treated mice
    Norton, Todd
    Lynn, Miriam Anne
    Rossouw, Charne
    Abayasingam, Arunasingam
    Perkins, Griffith
    Hissaria, Pravin
    Bull, Rowena Anne
    Lynn, David John
    GUT, 2024, 73 (07) : 1222 - 1224
  • [37] Neutralizing antibodies and T-cell responses to inactivated SARS-CoV-2 vaccine in COVID-19 convalescents one and a half years after infection
    Yan, Li-Na
    Li, Dan
    Jiang, Ze-Zheng
    Xiao, Xiao
    Yu, Xue-Jie
    VIRUS RESEARCH, 2023, 323
  • [38] Multiple sclerosis-disease modifying therapies affect humoral and T-cell response to mRNA COVID-19 vaccine
    Dominelli, Federica
    Zingaropoli, Maria Antonella
    Tartaglia, Matteo
    Tortellini, Eeva
    Guardiani, Mariasilvia
    Perri, Valentina
    Pasculli, Patrizia
    Ciccone, Federica
    Malimpensa, Leonardo
    Baione, Viola
    Napoli, Anna
    Gaeta, Aurelia
    Lichtner, Miriam
    Conte, Antonella
    Mastroianni, Claudio Maria
    Ciardi, Maria Rosa
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [39] T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine
    Atanackovic, Djordje
    Kreitman, Robert J.
    Cohen, Jeffrey
    Hardy, Nancy M.
    Omili, Destiny
    Iraguha, Thierry
    Burbelo, Peter D.
    Gebru, Etse
    Fan, Xiaoxuan
    Baddley, John
    Luetkens, Tim
    Dahiya, Saurabh
    Rapoport, Aaron P.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (07)
  • [40] Impaired mRNA Based COVID-19 Vaccine Response in Patients with B-Cell Malignancies after CD19 Directed CAR-T Cell Therapy
    Dahiya, Saurabh
    Luetkens, Tim
    Avila, Stephanie
    Dahiya, Saurabh
    Margiotta, Philip
    Hankey, Kim
    Lesho, Patricia
    Bauman, Sherri
    Smith, Nancy
    Ruehle, Kathleen
    Lee, Seung-Tae
    Law, Jennie Y.
    Baddley, John
    Kocoglu, Mehmet Hakan
    Yared, Jean A.
    Hardy, Nancy M.
    Rapoport, Aaron P.
    Atanackovic, Djordje
    BLOOD, 2021, 138